GYRE THERAPEUTICS, INC.

SAN DIEGO, CA · CIK 0001124105 · Biotech · Public

Engineered cell therapies for retinal diseases using ex vivo cell modification

gyretx.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$5.0M
1 Form D · Nov 2023
35 months since last filing
Contracts
—
No federal contracts on record
Patents
2
0 granted · 2 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$5,000,000
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2501ARTELO BIOSCIENCES, INC.—$33M
2502Celmatix Inc.—$20M
2503Exciva——
2504GYRE THERAPEUTICS, INC.—$5.0M
2505VIVOVERSE, LLC——
2506Kamau Therapeutics, Inc.—$5.0M
2507CONFLUENCE LIFE SCIENCES, INC.—$5.7M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 10 related persons
  • Gordon CarmichaelDirector
  • Ruoyu ChenExecutive Officer
  • Thomas EastlingDirector
  • Ying LuoDirector
  • Songjiang MaDirector · Executive Officer
  • Usman NassimDirector
  • Renate ParryDirector
  • Charles WuDirector · Executive Officer
  • Han YingDirector
  • Weiguo YuExecutive Officer

Patents

USPTO · 0 granted of 2
  • Pharmaceutical Hydronidone Formulations For Diseasesapplication
  • Application Of Hydronidone In Preparation Of Drug For Treating Or Preventing Chronic Hepatitis B With Liver Fibrosisapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.